Surmodics to Present at 7th Annual Intellisight Investor Conference

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will participate in the 7^th Annual Intellisight Conference. The two-day conference, hosted by the CFA Society of Minnesota, will take place this year on Tuesday and Wednesday, August 14 and 15, in Minneapolis.

Tim Arens, interim vice president of finance and chief financial officer, will present on Wednesday, August 15, at 2:30 p.m. CT (3:30 p.m. ET). The presentation will be webcast live and can be accessed by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com and clicking on the webcast link.

About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address unmet clinical needs for its medical device customers and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180807005131/en/